Aducanumab: A Deep Dive into BIIB037 and its Impact A drug, initially known as BIIB037, constitutes a complex effort to treat early-stage Alzheimer's illness. Developed by Biogen, aducanumab works by targeting https://www.targetmol.com/compound/aducanumab